Navigation Links
DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology

ient compliance. In addition, by combining rapid release and extended release characteristics, DuoCort's new tablet also delivers a more physiological dose of hydrocortisone, better mimicking the body's natural cortisol serum profile.

About adrenal insufficiency

Recent research on adrenal insufficiency patients taking currently available glucocorticoid replacement therapy demonstrates reduced bone density and unfavourable cardiovascular risk profiles. Recent data also suggest an almost 3-fold increased mortality. Chronic adrenal insufficiency is a rare disease that affects at least 125,000 patients in the European Union.

About DuoCort AB

DuoCort is a drug development company focussed on improving glucocorticoid therapy in several areas of medical need. DuoCort was founded in 2003 by PULS, an early-stage life sciences investment and business development group (www.pulsinvest.se). www.duocort.com

This information was brought to you by Cision http://newsroom.cision.com

Contact

DuoCort
Greg Batcheller, CEO, +46 73 391 9608


'"/>




Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 1Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 1SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 4Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 1Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 2Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 3 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 1 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 2
...NGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap...maceutical company focused on,the discovery and de...ay announced encouraging preclinical data of AV-41...nhibitor of EGFR/HER2 using,AVEO,s unique EGFR mut...he results from the preclinical study showed that ...
...r Presentation on April 17, 2007 at AACR, SAN DIEG...aceuticals, Inc. presented data from an in vitro s...promotes natural killer (NK),cell-mediated anti-tu...ysis of tumor cells and enhanced antibody-dependen...esentation at the Annual,Meeting of the American A...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
(Date:12/2/2008).... 2 With the bright lights, sweet ...olidays may be an exciting time of year for any ch... especially with today,s tough economy. Whether i...tying their wallets, or spending hours traveling t...lax, and even less time to be alone and romantic w...
(Date:12/2/2008)...ologic-Treated Psoriasis Patients Will Double by 2...rces , , WALTHAM, Mass., Dec. 2 /PRNewswire...g research and advisory firms for pharmaceutical a...particularly Centocor/Janssen-Cilag,s Stelara and ...severe psoriasis drug market to more than double t...
(Date:12/2/2008)... New research estimates that 1500 l... with the highest risk-adjusted,mortality rates (...ery,performed as well as hospitals with the lowes...ity rate for women was higher than men regardless ...eased as performance declined.,The study ranked U...
(Date:12/2/2008)... 2 Mylan Inc. (NYSE: M...Mylan Pharmaceuticals Inc., have entered,into a s...Corp., Novartis,Corp. and Novartis International ...ion of Novartis, Femara(R). , Mylan,s Vice ...e very,pleased to have reached this agreement, wh...
Breaking Medicine News(10 mins):Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 2Health News:New Research Estimates 1500 Lives Could Be Saved Annually if the Lowest Performing Hospitals for Coronary Artery Bypass Graft Surgery Performed as Well as Top-ranking Hospitals 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
...be a promising treatment, according to a new study...ecial needle into the tumor. A current is then pas...sue and ablate, or eliminate, it. The research fin... also do not appear to have any serious complicati...
...n treatment for a specific type of testicular canc...pically treated by // removal of the testicle foll... of developing a second cancer in another organ up...ed more than 540 patients to receive a single cour...
...a new vaccine to children. Researchers found that ...nvasive pneumococcal disease (pneumonia or meningi... 2002, 14,730 fewer cases occurred among whites an...d with the average number in two prevaccine years,...
...ion that can cause death within days or even hours...ive care intended to keep patients alive long enou...r a donor organ becomes available for transplantat... die unless they receive a liver transplant. A bio...
Other Medicine News:
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: